Biogen Reports Long-Term EMERGE/ENGAGE Data for Aduhelm in Alzheimer's Disease

Biogen today presented long-term follow-up data from the EMERGE and ENGAGE trials evaluating Aduhelm (aducanumab) in patients with early Alzheimer's disease. The data showed that Aduhelm maintained significant amyloid plaque reduction over extended treatment, with patients who received higher doses showing greater amyloid clearance.